FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032970726> ?p ?o ?g. }

• W3032970726 abstract "Our study aimed to compare efficacy and safety of Hetero's adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis (RA) concomitant on methotrexate (MTX) therapy.Patients (n = 168) were randomized (2:1) to receive either test or reference product for 24 weeks with concomitant MTX. Proportion of patients achieving American College of Rheumatology 20 (ACR20) criteria at week 12 was the primary endpoint. Changes in Disease Activity Score of 28 joints-C-reactive protein (DAS28-CRP), Health Assessment Questionnaire-Disability Index (HAQ-DI), and patients achieving ACR20 at week 24, ACR50/70 at weeks 12 and 24 were secondary endpoints.Patients achieving ACR20 responses with test (96.43%) were similar to reference (96.43%) in intention-to-treat (ITT) analysis at week 12. Proportional difference (PD) between groups (PD [95% CI] 0.0 [- 6.0, 6.0], p = 1.000) for ACR20 at week 12 for ITT analysis showed lower limit of the two-sided 95% CI was above the pre-specified noninferiority margin of - 15%. Similar trend in PP analysis (PD [95% CI] 0.0 [- 0.03, 0.07], p = 1.000), confirmed therapeutic equivalence. No significant difference was noted between arms for patients attaining ACR20 at week 24 and ACR50/70 at weeks 12 and 24 (all p > 0.05). DAS28-CRP and HAQ-DI were similar between groups. Total of 54 patients reported 88 AEs during the study. Out of these, 60 AEs were reported in 34 patients with Hetero-Adalimumab and 28 AEs were reported in 20 patients with Reference-Adalimumab. Total two patients, one in each group reported two serious adverse events (Sinusitis and Viral infection) during the study and resolved completely. No deaths and no life threatening AEs were reported.Results demonstrated Hetero's adalimumab is as effective and well tolerated as reference adalimumab in patients with active RA concomitantly on MTX therapy.CTRI/2016/04/006884, Registered on 28/04/2016." @default.
• W3032970726 created "2020-06-12" @default.
• W3032970726 creator A5001879581 @default.
• W3032970726 creator A5006426025 @default.
• W3032970726 creator A5008154828 @default.
• W3032970726 creator A5014174856 @default.
• W3032970726 creator A5014448801 @default.
• W3032970726 creator A5014755176 @default.
• W3032970726 creator A5024722457 @default.
• W3032970726 creator A5028065476 @default.
• W3032970726 creator A5037937576 @default.
• W3032970726 creator A5038561137 @default.
• W3032970726 creator A5038888103 @default.
• W3032970726 creator A5051176132 @default.
• W3032970726 creator A5063875127 @default.
• W3032970726 creator A5069820622 @default.
• W3032970726 creator A5072490980 @default.
• W3032970726 creator A5073703528 @default.
• W3032970726 creator A5074814278 @default.
• W3032970726 creator A5079653941 @default.
• W3032970726 creator A5079905099 @default.
• W3032970726 creator A5084350783 @default.
• W3032970726 date "2020-06-04" @default.
• W3032970726 modified "2023-10-18" @default.
• W3032970726 title "Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy" @default.
• W3032970726 cites W1686511800 @default.
• W3032970726 cites W1761300068 @default.
• W3032970726 cites W1979364075 @default.
• W3032970726 cites W1996389186 @default.
• W3032970726 cites W2025001196 @default.
• W3032970726 cites W2031388906 @default.
• W3032970726 cites W2046628605 @default.
• W3032970726 cites W2060200463 @default.
• W3032970726 cites W2097291747 @default.
• W3032970726 cites W2103187999 @default.
• W3032970726 cites W2103270747 @default.
• W3032970726 cites W2115008314 @default.
• W3032970726 cites W2119046820 @default.
• W3032970726 cites W2128952811 @default.
• W3032970726 cites W2136585211 @default.
• W3032970726 cites W2149065814 @default.
• W3032970726 cites W2168711492 @default.
• W3032970726 cites W2262703742 @default.
• W3032970726 cites W2332671719 @default.
• W3032970726 cites W2623157416 @default.
• W3032970726 cites W2737167414 @default.
• W3032970726 cites W2791224008 @default.
• W3032970726 cites W2794809019 @default.
• W3032970726 cites W2885678144 @default.
• W3032970726 cites W2895590824 @default.
• W3032970726 cites W2911447041 @default.
• W3032970726 cites W3006080604 @default.
• W3032970726 cites W3010345805 @default.
• W3032970726 cites W4249063051 @default.
• W3032970726 cites W4319053946 @default.
• W3032970726 cites W4323053507 @default.
• W3032970726 doi "https://doi.org/10.1186/s41927-020-00124-9" @default.
• W3032970726 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7271501" @default.
• W3032970726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32518895" @default.
• W3032970726 hasPublicationYear "2020" @default.
• W3032970726 type Work @default.
• W3032970726 sameAs 3032970726 @default.
• W3032970726 citedByCount "5" @default.
• W3032970726 countsByYear W30329707262021 @default.
• W3032970726 countsByYear W30329707262022 @default.
• W3032970726 countsByYear W30329707262023 @default.
• W3032970726 crossrefType "journal-article" @default.
• W3032970726 hasAuthorship W3032970726A5001879581 @default.
• W3032970726 hasAuthorship W3032970726A5006426025 @default.
• W3032970726 hasAuthorship W3032970726A5008154828 @default.
• W3032970726 hasAuthorship W3032970726A5014174856 @default.
• W3032970726 hasAuthorship W3032970726A5014448801 @default.
• W3032970726 hasAuthorship W3032970726A5014755176 @default.
• W3032970726 hasAuthorship W3032970726A5024722457 @default.
• W3032970726 hasAuthorship W3032970726A5028065476 @default.
• W3032970726 hasAuthorship W3032970726A5037937576 @default.
• W3032970726 hasAuthorship W3032970726A5038561137 @default.
• W3032970726 hasAuthorship W3032970726A5038888103 @default.
• W3032970726 hasAuthorship W3032970726A5051176132 @default.
• W3032970726 hasAuthorship W3032970726A5063875127 @default.
• W3032970726 hasAuthorship W3032970726A5069820622 @default.
• W3032970726 hasAuthorship W3032970726A5072490980 @default.
• W3032970726 hasAuthorship W3032970726A5073703528 @default.
• W3032970726 hasAuthorship W3032970726A5074814278 @default.
• W3032970726 hasAuthorship W3032970726A5079653941 @default.
• W3032970726 hasAuthorship W3032970726A5079905099 @default.
• W3032970726 hasAuthorship W3032970726A5084350783 @default.
• W3032970726 hasBestOaLocation W30329707261 @default.
• W3032970726 hasConcept C111113717 @default.
• W3032970726 hasConcept C112705442 @default.
• W3032970726 hasConcept C126322002 @default.
• W3032970726 hasConcept C168563851 @default.
• W3032970726 hasConcept C198451711 @default.
• W3032970726 hasConcept C203092338 @default.
• W3032970726 hasConcept C2777575956 @default.
• W3032970726 hasConcept C2779384505 @default.
• W3032970726 hasConcept C2780132546 @default.
• W3032970726 hasConcept C2781059491 @default.
• W3032970726 hasConcept C71924100 @default.
• W3032970726 hasConceptScore W3032970726C111113717 @default.

• next